Drug Trial Radar · NCT07903415
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
Nov 5, 2026
Primary completion
Jan 26, 2031
Study completion Jan 26, 2032
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts of the body). PF-08098488 is being studied as a possible treatment for certain types of cancer. These include non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, and esophageal cancer. This study will also help researchers learn how the study medicine moves through and affects the body. This study is seeking adults who: * Have advanced non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, or esophageal cancer. * Have received at least 1 previous treatment for their cancer. * Have cancer that has grown, returned, or is no longer responding to available treatments. All participants in this study will receive PF-08098488 as an IV infusion (given directly into a vein) at the study clinic. Researchers will study different dose levels and dosing schedules to find the dose that is safe and may work best. Participants will be monitored closely during treatment, especially after their first infusion. They may continue receiving the study medicine as long as their cancer is not getting worse and they are tolerating treatment. The study includes a screening period of up to 28 days. Participants will have regular visits to the study clinic for treatment and health assessments. These assessments include scans to monitor the cancer and blood sample collection. Tumor tissue samples will also be collected when available or medically feasible. After treatment ends, participants will have a follow-up visit about 1 month later. They will then be contacted about every 12 weeks to check on their health.
Conditions
- Pancreatic Ductal Adenocarcinoma
- Esophageal Cancer
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Gastric Carcinoma
- Gastroesophageal Junction Adenocarcinoma
Interventions
PF-08098488Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: Start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy (whichever occurs first)
- Part 1: Recommended Monotherapy Dose(s) for Expansion (RDEM)Time frame: From first dose through completion of Part 1, an average of 1 year
- Part 2: Recommended Monotherapy Dose for Further DevelopmentTime frame: From first dose through completion of Part 2, an average of 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
START Midwest, LLC
Grand Rapids, Michigan · Recruiting
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
START San Antonio, LLC
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.